ResearchGenomic Landscape of Clinically Acquired Resistance Alterations in Patients Treated with KRAS Inhibitors
ResearchGeneration of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
ResearchDiagnostic Performance of PSMA PET/MRI in Characterizing LI-RADS 3 Observations in Patients with Cirrhosis
ResearchMAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response
ResearchAllosteric PI3K-alpha Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
ResearchFGFR Inhibition Blocks NF-kB-Dependent Glucose Metabolism and Confers Metabolic Vulnerabilities in Cholangiocarcinoma
ResearchFGFR inhibition blocks NF-κB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
ResearchGeneration of a Biliary Tract Cancer Cell Line Atlas Reveals Molecular Subtypes and Therapeutic Targets
ResearchAllosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
ResearchFGFR inhibition blocks NF-kB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
ResearchAllosteric PI3Kα Inhibition Overcomes On-Target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations
ResearchLandscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma